For the Quarter Ending March 2026
Levodopa Prices in APAC
- In China, the Levodopa Price Index fell by 7.06% quarter-over-quarter, driven by softer export bookings.
- The average Levodopa price for the quarter was approximately USD 41463.33/MT, reflecting balanced export demand.
- Levodopa Spot Price tightened after two coastal catechol lines curtailed, trimming export parcels, tightening availability.
- Levodopa Price Forecast anticipates modest near-term upside as buyers restock amid constrained spot supply cautiously.
- Levodopa Production Cost Trend stayed flat as L-tyrosine supply and power tariffs kept costs steady.
- Levodopa Demand Outlook strengthened as North American and European formulators accelerated procurement to diversify sourcing.
- Levodopa Price Index improved month-on-month in March as inventories fell and operating rates eased slightly.
- Exporters maintained disciplined shipments while Levodopa Spot Price reacted to freight and port logistics constraints.
Why did the price of Levodopa change in March 2026 in APAC?
- Coastal catechol unit curtailments removed roughly 150 tonnes, tightening export availability and reducing warehouse cover.
- Orders from US and European formulators accelerated, increasing export demand and lifting FOB Shanghai offers.
- Stable feedstock and unchanged power tariffs limited cost pressure, so price rise reflected supply-demand imbalance.
Levodopa Prices in Europe
- In Germany, the Levodopa Price Index fell by 7.03% quarter-over-quarter, reflecting constrained margins and pressures.
- The average Levodopa price for the quarter was approximately USD 41560/MT, reflecting trading activity patterns.
- Levodopa Spot Price firmed on tighter availability as Rhine low-water and logistics surcharges constrained supply.
- Levodopa Price Forecast points to modest near-term gains driven by replenishment buying and pharmaceutical procurement.
- Levodopa Production Cost Trend flat as feedstock and energy costs showed limited movement across origins.
- Levodopa Demand Outlook stays steady, anchored in inelastic Parkinsons therapy demand and routine tender-driven procurement.
- Levodopa Price Index volatility limited as imports from India, Spain, and Italy maintained inventory cushions.
- Major origin plants reported operations, while export flows and competitive offers constrained German spot availability.
Why did the price of Levodopa change in March 2026 in Europe?
- Rhine low-water increased inland trucking and handling costs, temporarily tightening prompt availability and pushing landed costs.
- Steady pharmaceutical demand and thin formulators inventories encouraged importers to accept premiums, supporting modest price uptick.
- Stable feedstock and energy costs restrained upward pressure, while freight surcharges and Euro stability supported prices.
Levodopa Prices in North America
- In the USA, the Levodopa Price Index fell by 7.03% quarter-over-quarter, prompting negotiation among generic formulators.
- The average Levodopa price for the quarter was approximately USD 41,561.67/MT, reflecting CFR Los Angeles dynamics.
- Levodopa Spot Price softened as freight rose and spot availability tightened, lifting CFR landed costs.
- Levodopa Price Forecast shows modest near-term strengthening amid logistic pressure and selective restocking by formulators.
- Levodopa Production Cost Trend highlighted higher freight and bunker surcharges, raising delivered costs for US importers.
- Levodopa Demand Outlook remained stable with steady prescriptions yet increased buyer price sensitivity and negotiation.
- Levodopa Price Index movements reflected container freight swings and resilient export supply from India and China.
- Spot offers from exporters contained volatility while Levodopa Spot Price stayed consistently aligned with contract quotations.
Why did the price of Levodopa change in March 2026 in North America?
- Higher Shanghai-to-Houston container freight increased landed costs, transmitting upward pressure to CFR Levodopa quotations domestically.
- Pharmacy shortages and intensified hospital procurement accelerated buying, tightening spot availability and supporting price firmness.
- Export manufacturing steady but elevated bunker surcharges and logistics transmitted higher delivered costs to importers.
For the Quarter Ending December 2025
North America
- In USA, the Levodopa Price Index rose by 1.82% quarter-over-quarter, due to freight, cautious restocking.
- The average Levodopa price for the quarter was approximately USD 63351.67/MT, CFR Los Angeles tallies.
- Levodopa Price Index showed monthly gains as freight declines partially offset steady pharmaceutical offtake levels.
- Levodopa Spot Price remained firm as buyers preferred replacement purchases amid normalized imports and logistics.
- Levodopa Production Cost Trend stayed stable with feedstock prices steady and manufacturers maintaining consistent output.
- Levodopa Demand Outlook remained constructive as ageing demographics and clinical activity supported steady prescription volumes.
- Levodopa Price Forecast indicates modest controlled increases as freight normalizes and buyers rebuild limited inventories.
- Inventory comfort and measured export demand left sellers disciplined, keeping upward price movements moderate only.
Why did the price of Levodopa change in December 2025 in North America?
- Lower ocean freight in December reduced landed costs, offsetting firm pharmaceutical demand, yielding near-flat net movement.
- Elevated earlier freight surcharges and cautious seller offers sustained upward pressure despite comfortable global inventories.
- Buyers rebuilding lean stocks and ongoing clinical demand supported procurement, preventing price declines in December.
APAC
- In China, the Levodopa Price Index rose by 1.85% quarter-over-quarter, driven by firm export demand and tighter inventories.
- The average Levodopa price for the quarter was approximately USD 63266.67/MT, reflecting tightened export procurement.
- Levodopa Spot Price recorded marginal gains as buyers advanced purchases ahead of year-end formulation campaigns.
- Levodopa Price Forecast shows mild upside as steady demand and higher freight maintain price discipline.
- Levodopa Production Cost Trend reflects elevated air freight and compliance costs pressuring producer margins modestly.
- Levodopa Demand Outlook remains constructive due to Parkinsons therapy output and export restocking by formulators.
- Levodopa Price Index stayed firm as inventories tightened and selective forward buying reinforced seller confidence.
- Major Chinese plants maintained routine output; port efficiency improved though seasonal logistics slowdowns persisted modestly.
Why did the price of Levodopa change in December 2025 in APAC?
- Supply constraints from earlier flooding and intermittent downtime tightened availability and supported FOB price increases.
- Elevated air-freight and port fees raised logistics costs, prompting suppliers to pass higher FOB values.
- Firm export demand and forward buying amid tightening inventories sustained upward pricing momentum during December.
Europe
- In Germany, the Levodopa Price Index rose by 1.80% quarter-over-quarter, reflecting constrained supply and logistics.
- The average Levodopa price for the quarter was approximately USD 63345.00/MT, reflecting CFR Hamburg costs.
- Levodopa Spot Price stayed firm as buyers restocked ahead of holidays, limiting downward price pressure.
- Levodopa Price Forecast indicates modest gains from freight and exchange-rate effects, followed by early-year correction.
- Levodopa Production Cost Trend shows upward pressure from energy and compliance costs, supporting landed prices.
- Levodopa Demand Outlook remains steady with ageing population-driven offtake and low price elasticity supporting purchases.
- Levodopa Price Index was amplified by precautionary restocking and limited export reallocations from constrained suppliers.
- Major supplier operations were broadly normal, keeping inventories adequate and capping Levodopa Price Index spikes.
Why did the price of Levodopa change in December 2025 in Europe?
- Constrained API exports and selective Indian allotments reduced available cargoes, tightening spot availability and lifting landed costs.
- Precautionary German restocking and hospital forward buying increased near-term demand, outweighing otherwise stable monthly volumes.
- Elevated freight and port-related surcharges plus modest currency weakness amplified CIF prices despite orderly import arrivals.
For the Quarter Ending September 2025
North America
- In the USA, the Levodopa Price Index fell by 1.19% quarter-over-quarter, Q3 2025, due to destocking.
- The average Levodopa price for the quarter was approximately USD 62216.67/MT, weighted by Los Angeles volumes.
- Levodopa Spot Price remained pressured through the quarter amid logistical corrections and subdued booking activity.
- Levodopa Price Forecast indicates modest stabilization with upward bias as restocking emerges and imports normalize.
- Levodopa Production Cost Trend was stable; freight cost correction reduced landed cost pressure during the quarter.
- Levodopa Demand Outlook remains tepid with cautious pharmacy buying and seasonal uptick failing to materialize.
- Levodopa Price Index sensitivity increased as strategic stockpiling earlier in quarter then accelerated inventory liquidation.
- Market participants noted balanced import volumes and disciplined selling, constraining volatility while margins slightly adjusted.
Why did the price of Levodopa change in September 2025 in North America?
- Destocking and earlier strategic stockpiles reduced immediate purchasing, weakening demand and further pressuring mid-quarter prices.
- Ocean freight corrections and easing logistics lowered landed costs, translating into reduced upward price momentum.
- Uncertain trade policy and tariff threats provoked frontloading earlier, then softened bookings causing price moderation.
APAC
- In China, the Levodopa Price Index fell by 1.2% quarter-over-quarter, reflecting weak export demand and inventories.
- The average Levodopa price for the quarter was approximately USD 62116.67/MT, reflecting subdued export and domestic purchasing activity.
- Levodopa Price Forecast points to mild recovery as shipping costs rise and producers manage production schedules.
- Levodopa Production Cost Trend showed easing input prices but episodic weather disruptions increased operational expenses for some manufacturers.
- Levodopa Demand Outlook remains cautious with western buyers restocking selectively while overall consumption stays subdued.
- Levodopa Price Index and Spot Price volatility reflected inventory accumulation, competitive export pricing, and seasonal procurement ahead.
- Rising unsold inventories pressured margins while strategic export demand spurts produced short-lived upward price adjustments.
- Major Chinese producers operated steady utilization, adapting offers and flexible volumes to stimulate offtake amid soft markets.
Why did the price of Levodopa change in September 2025 in APAC?
- Weak international demand reduced buying urgency and increased competition among exporters, pressuring export FOB prices.
- Lower logistics costs and abundant shipping capacity gave purchasers leverage, contributing to downward price pressure.
- Domestic overcapacity and accumulating inventories forced sellers into flexible pricing strategies to maintain order flow.
Europe
- In Germany, the Levodopa Price Index fell by 1.1129% quarter-over-quarter, reflecting surplus inventories and conservative purchasing.
- The average Levodopa price for the quarter was approximately USD 62223.67/MT, landed costs and logistics adjustments.
- Levodopa Spot Price remained pressured by elevated stock levels and muted spot buying across distributors and wholesalers.
- Levodopa Price Forecast indicates upward adjustments as Q3 restocking and logistical costs normalize, challenging tolerance levels.
- Levodopa Production Cost Trend showed limited inflationary feedstock impact, with freight delays influencing landed costs and margins.
- Levodopa Demand Outlook remains cautious; hospital and distributor buying disciplined, avoiding speculative inventory accumulation across channels.
- Levodopa Price Index movements were influenced by port congestion, delayed freight surcharges, and deferred procurement behavior patterns.
- Major supplier operational status was stable, enabling balanced imports despite transport bottlenecks and seasonal surcharges affecting timings.
Why did the price of Levodopa change in September 2025 in Europe?
- Elevated inventories and deliberate destocking reduced buying urgency, easing price pressures in the market effectively.
- Logistics disruptions and delayed freight surcharges temporarily increased landed cost uncertainty, prompting cautious purchasing decisions.
- Steady end-user demand matched improved incoming shipments, limiting spot tightness and restraining further price escalation.
For the Quarter Ending June 2025
North America
- The Levodopa Price Index in the USA declined from USD 65,100/MT in April to USD 61,687/MT in June, reflecting an overall 8.49% quarterly drop due to persistent tariff pressure and inventory-heavy conditions.
- In April 2025, the product spot price softened as importers absorbed some of the 145% China-origin tariff costs while strategic frontloading in March built up stocks, limiting new orders and reducing the product demand outlook.
- Despite the high tariff structure, April saw ample inventories and low booking momentum as buyers paused purchases in anticipation of trade updates, adding to bearish pressure on the product price forecast.
- In May, the Price Index dipped further as U.S.–China tariff talks led to a temporary rollback, but uncertainty over compliance timelines and the U.S. executive drug price mandate (30–80% cuts) deterred procurement, intensifying the weak product demand outlook.
- A 20.8% MoM fall in containerized imports during May suggested that pharmaceutical buyers were recalibrating supply chains and holding off on commitments, further dragging the Price Index downward.
- The product production cost trend stabilized briefly in May due to lower inbound volumes and slower trade, but price recovery was capped by subdued buyer interest and cautious downstream sentiment.
- June 2025 continued the downtrend in product spot prices as buyers liquidated inventories and held off on summer-peak bookings, with the Price Index falling below USD 61,700/MT.
- Weak freight rates from Asia and a visible destocking trend in U.S. pharma hubs in June underscored surplus availability, confirming bearish signals in the product price forecast and compounding the already soft product demand outlook.
- By late June, wholesalers and mid-tier distributors rushed to normalize inventory before fiscal close, contributing to weaker downstream demand and holding back any chance of price stabilization.
- In July 2025, prices are likely to increase moderately as Q3 contract negotiations begin, reviving short-term demand, while cautious supplier behavior and slower replenishments may cause a mild squeeze in supply, lifting the Price Index slightly.
APAC
- The Levodopa Price Index in China fell from USD 65,000/MT in April to USD 61,500/MT in June, reflecting a decline across Q2 2025.
- In April, persistent inventory overhang and weak overseas interest—particularly from the U.S. due to 145% tariffs—forced exporters to slash the product spot price to accelerate offtake.
- April’s sharp decline in China’s manufacturing PMI to 49.0 indicated contraction, tightening the product production cost trend and undermining pricing power.
- By May, manufacturers struggled with unsold stock and missed export targets; the product demand outlook remained subdued as foreign buyers adopted a wait-and-see approach amid ongoing trade uncertainty.
- Domestic consumption during May also stagnated, compounded by the extended Labor Day holiday and delayed shipments.
- In June, despite stable output, oversupply intensified; buyers refrained from fresh procurement, citing adequate inventory levels and soft global demand.
- Falling freight rates in June exerted further pressure on the product spot price, as buyers negotiated harder under reduced logistics costs.
- China's June PPI decline of 3.6% signaled a deflationary trend, weakening product production cost trend across pharmaceuticals.
- Exporters turned to aggressive price competition in June to stimulate lagging international demand, especially in Western markets.
- Product price forecast for July 2025 indicates a continued decrease, driven by excess inventory, risk-averse buyers, and low consumption expectations.
Europe
- The Levodopa Price Index in Germany dropped by 8.44% in April, followed by declines of 4.63% in May and 0.75% in June, bringing the average Levodopa Spot Price to USD 61,610/MT by the end of Q2.
- In April, the German market experienced a sharp Price Index decline due to an influx of diverted U.S.-bound cargo, elevated inventories from pre-holiday stocking, and subdued product demand outlook, compelling suppliers to cut prices to maintain throughput.
- May's Price Index slide was influenced by ongoing supply excess from Chinese rerouted shipments, cautious procurement by pharmaceutical players, and logistical disruptions at major Northern European ports like Hamburg and Antwerp.
- Retail sector demand remained weak in May, as persistent inflation (CPI at 2.1%) curtailed pharmaceutical spending, reinforcing a tepid product demand outlook and triggering further reductions in product spot price.
- The product production cost trend remained under control in May as European buyers benefited from stable landed costs, despite blank sailings and port congestion.
- In June, quarter-end inventory liquidation and conservative procurement strategies caused the Price Index to dip again, as importers avoided speculative buying and focused on minimizing stock before mid-year closure.
- Delays in implementing Peak Season Surcharges (PSS) by ocean carriers helped prevent a spike in product production cost trend, keeping freight-linked costs stable and temporarily supporting price levels.
- Import flow remained uninterrupted throughout the quarter, but mounting inventories and cautious demand created a persistent oversupply condition, shaping a weak product price forecast outlook for July.
- Buyers are expected to re-enter the market in July for Q3 contract purchases, injecting fresh demand; however, supply might remain slightly constrained due to import lags and hesitant supplier positions, potentially lifting the Price Index.
- Overall, Levodopa prices are likely to increase in July 2025, driven by contract-based restocking and anticipated tightening in availability, marking a potential shift from the prolonged Q2 downtrend.
